{"id":"NCT02954887","sponsor":"Jazz Pharmaceuticals","briefTitle":"Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)","officialTitle":"A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-12","primaryCompletion":"2019-06-13","completion":"2019-06-13","firstPosted":"2016-11-04","resultsPosted":"2020-07-23","lastUpdate":"2022-09-02"},"enrollment":9,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Infantile Spasms"],"interventions":[{"type":"DRUG","name":"GWP42003-P","otherNames":["CBD","Cannabidiol"]}],"arms":[{"label":"GWP42003-P","type":"EXPERIMENTAL"}],"summary":"This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase, and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive GWP42003-P.","primaryOutcome":{"measure":"Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From signing of informed consent up to Day 417","effectByArm":[{"arm":"GWP42003-P OS","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":7,"countries":["United States","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":9},"commonTop":["Upper respiratory tract congestion","Pyrexia","Irritability","Blood triglycerides increased","Anaemia"]}}